Fleury SA
BOVESPA:FLRY3
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.47
18.58
|
| Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fleury SA
Fleury SA
Cost of Revenue
Fleury SA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fleury SA
BOVESPA:FLRY3
|
Cost of Revenue
-R$5.5B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-16%
|
|
|
Oncoclinicas do Brasil Servicos Medicos SA
BOVESPA:ONCO3
|
Cost of Revenue
-R$3.6B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Centro de Imagem Diagnosticos SA
BOVESPA:AALR3
|
Cost of Revenue
-R$834.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
D
|
Diagnosticos da America SA
BOVESPA:DASA3
|
Cost of Revenue
-R$11B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-20%
|
|
Fleury SA
Glance View
Fleury SA engaged in the provision of medical diagnostic services. The company is headquartered in Sao Paulo, Sao Paulo and currently employs 20,800 full-time employees. The company went IPO on 2009-12-16. The Company’s activities are divided into three business lines: Patient Service Centers (PSC), B2B and Dental Diagnosis. The PCS division offers private medical diagnostics. The B2B division is responsible for clinical analysis and diagnostic imaging in partner hospitals, as well as tests for laboratories, hospitals and clinics throughout Brazil. The Dental Diagnosis division provides dental diagnostic imaging through Papaiz Associados Diagnosticos por Imagem SA, a joint venture with Odontoprev SA. The firm operates through several brands, such as Fleury Medicina e Saude, Clinica Felippe Mattoso e Weinmann, a+ Medicina Diagnostica, Diagnoson a+, Diagmax and Inlab, among others.
See Also
What is Fleury SA's Cost of Revenue?
Cost of Revenue
-5.5B
BRL
Based on the financial report for Sep 30, 2024, Fleury SA's Cost of Revenue amounts to -5.5B BRL.
What is Fleury SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-16%
Over the last year, the Cost of Revenue growth was -27%. The average annual Cost of Revenue growth rates for Fleury SA have been -28% over the past three years , -17% over the past five years , and -16% over the past ten years .
You don't have any saved screeners yet
